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Abstract. 
 
In this paper, we show that substrate speciﬁcity
is primarily conferred on human mitotic cyclin-dependent
kinases (CDKs) by their subcellular localization. The
 
difference in localization of the B-type cyclin–CDKs
underlies the ability of cyclin B1–CDK1 to cause chromo-
some condensation, reorganization of the microtubules,
 
and disassembly of the nuclear lamina and of the Golgi
apparatus, while it restricts cyclin B2–CDK1 to disassem-
 
bly of the Golgi apparatus. We identify the region of
cyclin B2 responsible for its localization and show that
this will direct cyclin B1 to the Golgi apparatus and
confer upon it the more limited properties of cyclin B2.
Equally, directing cyclin B2 to the cytoplasm with the
 
NH
 
2 
 
terminus of cyclin B1 confers the broader properties
of cyclin B1. Furthermore, we show that the disassembly
of the Golgi apparatus initiated by either mitotic cyclin–
CDK complex does not require mitogen-activated
protein kinase kinase (MEK) activity.
Key words: cyclin • CDK • mitosis • protein kinase •
Golgi apparatus
 
Introduction
 
Cyclins play a vital role in controlling progress through the
eukaryotic cell cycle. They are required at each cell cycle
transition to activate their partner cyclin-dependent kinase
(CDK),
 
1
 
 for commitment to proliferation (at START or
the restriction point), initiation of DNA replication, and
initiation of mitosis (for reviews see Pines, 1995; Morgan,
1997). Different cyclin–CDK complexes are required at
each of these steps. In budding and fission yeasts, only one
CDK is required for the cell cycle and this binds different
cyclins at specific stages in the cell cycle. In animal cells,
different CDKs are active at different stages of the cell
cycle, but again each is able to bind more than one cyclin.
The question of whether and how cyclins impart speci-
ficity to their partner CDK is the subject of some debate
(Cross et al., 1999; Geng et al., 1999; for review see Roberts,
1999; Cross and Jacobson, 2000; Jacobson et al., 2000). In fis-
sion yeast, a single B-type cyclin–CDK complex, cdc13–
cdc2, is able to initiate either DNA replication (S phase)
or mitosis (M phase) depending on the amount of kinase
activity. Low kinase levels promote S phase, whereas high
amounts promote mitosis (Fisher and Nurse, 1996). These
results indicate that a cyclin may not change the substrate
specificity of a CDK because its biological action could be
determined by its relative affinity for S phase compared
with M phase substrates (Stern and Nurse, 1996). In con-
trast, there are clear differences in the biological properties
of different cyclin–CDK complexes in budding yeast. Bud-
ding yeast have two subfamilies of cyclins that cannot
substitute for each other: (a) three CLN cyclins that act
at START; and (b) six different B-type cyclins (CLB)
that control progress through S and M phases. There is
also specificity among the CLBs because the S phase
CLB5 and the M phase CLB2 cyclins cannot substitute for
each other when expressed at physiological levels (Cross
et al., 1999; Jacobson et al., 2000).
 
The molecular basis for the functional difference be-
tween CLB2 and CLB5 has not been definitively defined,
but attention has focused on differences in the “hydro-
phobic patch” that appears to play an important role in
substrate recognition by the cyclin A–CDK2 complex in
human cells (Schulman et al., 1998). The hydrophobic
patch is on the outer face of helix 1 of the cyclin box (Jef-
frey et al., 1995; Noble et al., 1997). Evidence from crystal
structures (Russo et al., 1996) and mutation studies impli-
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cated the hydrophobic patch in binding to the “Cy motif”
(R
 
 3 
 
L) of substrates such as p107 (Zhu et al., 1995), CDK
inhibitors such as p21
 
Cip1/Waf1
 
 and p27
 
Kip1
 
 (Chen et al.,
1995; Russo et al., 1996), and the CDK activator Cdc25A
(Saha et al., 1997). Thus, the hydrophobic patch may act as
a substrate targeting and specificity domain. In indirect
support of this, a form of CLB5 carrying a mutation in the
hydrophobic patch was partially defective in several as-
says, including the activation of late-firing origins of DNA
replication in S phase cells (Cross et al., 1999). Similarly,
mutating the hydrophobic patch in CLB2 reduced its abil-
ity to rescue yeast with a temperature-sensitive Clb2 gene
against the background of a strain lacking Clb1, Clb3, and
Clb4 (Cross and Jacobson, 2000).
There are two mammalian B-type cyclins, cyclins B1 and
B2, that differ in their NH
 
2 
 
termini but are 57% identical
in the rest of the protein (Chapman and Wolgemuth, 1993;
Jackman et al., 1995; Brandeis et al., 1998). Both cyclins
bind to CDK1 and are active only in mitosis (Jackman et
al., 1995), but only cyclin B1 is essential. Mice lacking cy-
clin B1 die in utero. Mice lacking cyclin B2 are smaller
than normal and have reduced litter sizes, indicating that
cyclin B2 does confer a growth advantage (Brandeis et al.,
1998). What underlies this difference between the cyclins?
Cyclin B2 is expressed at a much lower level than cyclin
B1; therefore, it is possible that cyclin B2 cannot compen-
sate for cyclin B1 because there is not enough of the pro-
tein in the cell (Brandeis et al., 1998). However, there is
also a striking difference between the proteins in their sub-
cellular localizations. Cyclin B1 is primarily cytoplasmic
but constantly shuttles between the nucleus and the cyto-
plasm in interphase (Hagting et al., 1998; Toyoshima et al.,
1998; Yang et al., 1998). At the end of prophase, it rapidly
translocates into the nucleus (Furuno et al., 1999; Hagting
et al., 1999) and then binds to the mitotic apparatus (Pines
and Hunter, 1991; Hagting et al., 1998; Clute and Pines,
1999). In contrast, mammalian cyclin B2 is primarily
bound to the Golgi apparatus in both interphase and mito-
sis (Jackman et al., 1995; Brandeis et al., 1998).
In mammalian cells, the Golgi apparatus disassembles at
mitosis in a carefully orchestrated manner (Misteli and
Warren, 1995a), such that approximately equal numbers
of vesicles are partitioned to each daughter cell (Shima et
al., 1997). This process is regulated by phosphorylation
(Misteli and Warren, 1995a,b; Lowe et al., 1998), but there
is a continuing debate over which protein kinase(s) is re-
sponsible. There is disagreement over whether the kinase
is a cyclin–CDK (Lowe et al., 1998, 2000), mitogen-acti-
vated protein (MAP) kinase kinase (MEK) (Acharya et
al., 1998; Colanzi et al., 2000), or both (Kano et al., 2000;
for review see Nelson, 2000).
In this paper, we have asked whether the subcellular dis-
tribution of the cyclins specifies the biological activity of the
cyclin–CDK complex and whether they can disassemble the
Golgi apparatus without MEK. We find that CDK1 has a
much more limited effect on subcellular architecture when
it is activated by the Golgi-associated cyclin B2 than when it
is activated by cyclin B1. Moreover, when cyclin B1 is tar-
geted to the Golgi apparatus by the NH
 
2 
 
terminus of cyclin
B2, it takes on the more restricted properties of cyclin B2.
These results may provide an explanation for why cyclin B2
is unable to complement cyclin B1 and demonstrate the
 
profound influence of subcellular localization on the biolog-
ical role of a cyclin–CDK. Moreover, we show that in living
cells, either cyclin B1–CDK1 or cyclin B2–CDK1 is suffi-
cient to initiate Golgi breakdown and that MEK is not re-
quired for Golgi apparatus disassembly in mitosis.
 
Materials and Methods
 
Cell Culture and Synchronization
 
HeLa and CHO cells were cultured in DME and Hams F-12 media, re-
spectively, supplemented with 10% FCS at 37
 
8
 
C, 10% CO
 
2
 
. To obtain
G0/G1 phase cells, CHO cells were cultured in Hams F-12 plus 0.1%
FBS on glass coverslips for at least 3 d and then microinjected in the
presence of 2% serum. To inhibit MEK activity, serum-starved cells
were incubated in 20 
 
m
 
M PD98059 and 25 
 
m
 
M U0126 for 1 h before in-
jection and subsequently for the duration of the experiment. Fresh
PD98059 was added every hour because of its short half-life in solution.
To analyze entry into mitosis in the presence of MEK inhibitors, CHO
cells were arrested in G0 by serum starvation for 36 h and then released
by addition of serum. After 18 h (G2 phase), 20 
 
m
 
M PD98059 and 25 
 
m
 
M
UO126 were added. Fresh medium and inhibitors were added every
hour until cells had reentered G1 phase 
 
z
 
6 h later. HeLa cells were syn-
chronized using a thymidine and aphidicolin regime as described previ-
ously (Heintz et al., 1983).
 
Construction of Chimeras and Expression Constructs
 
Chimeras were constructed by overlapping PCR using VENT polymerase
(Biolabs). The sequences of the oligonucleotides used are available on re-
quest. Constructs were cloned into eukaryotic expression vectors and se-
quenced on an automatic sequencer. The pCMX–cyclin B1–MmGFP,
pCMX–cyclin B1, and pCMX–cyclin B2 constructs have been described
previously (Jackman et al., 1995; Hagting et al., 1998). The cyclin B1–B2
chimera was constructed by ligating the myc epitope–tagged NH
 
2 
 
termi-
nus of cyclin B1 (base pairs 1–431) to the cyclin box and second cyclin fold
of cyclin B2 (base pairs 318–1191) via a HinD III restriction enzyme site.
The cyclin B2–B1 chimera was constructed by ligating the myc epitope–
tagged NH
 
2 
 
terminus of cyclin B2 (base pairs 1–391) to the cyclin box and
second cyclin fold of cyclin B1 (base pairs 503–1302) using Pst I and Nsi I
restriction enzyme sites.
 
Microinjection, Transfection, and Immunofluorescence
 
Cells were injected in the nucleus with expression constructs as de-
scribed previously (Hagting et al., 1998). Cells were incubated in CO
 
2
 
-
independent medium without phenol red (GIBCO BRL) during injec-
tion and subsequently incubated for 3–6 h at 37
 
8
 
C, 10% CO
 
2 
 
in Hams
F-12 medium plus 2% FCS. For transfection experiments, 293T cells (2
 
 3
 
10
 
7
 
) were transfected using calcium phosphate precipitation with 20 
 
m
 
g
of plasmids encoding cyclin B1 or B2 or the chimeras and 20 
 
m
 
g of
CDK1
 
AF
 
 expression vector with 30 
 
m
 
g of pING plasmid DNA for 24 h.
Cells were harvested 12 h after transfection. For immunofluorescence
analysis, cells were fixed in ice-cold methanol for 2 min. Antibodies
were diluted in 3% BSA and 0.2% Tween containing PBS. When using
the phospho-specific antibody, 2 
 
m
 
M microcystin was included in the
antibody dilution buffer. Primary antibodies were used at the following
dilutions and incubated for 1 h: anti–human cyclin B1 rabbit polyclonal
(1:400), anti–mouse cyclin monoclonal B1 V143 that does not cross-react
with human cyclin B1 (1:200) (a gift from J. Gannon and Tim Hunt,
Imperial Cancer Research Fund, London, UK), anti–cyclin B2 rabbit
polyclonal (1:25), anti–mannosidase II rabbit polyclonal (1:50), anti-
giantin monoclonal antibody (1:100), anti–
 
b
 
-tubulin mouse mono-
clonal (1:100) (Amersham Pharmacia Biotech), anti–nuclear lamin
rabbit polyclonal (1:200) (a gift from Larry Gerace, The Scripps Re-
search Institute, La Jolla, CA). Secondary antibodies linked to FITC,
Texas red, or Cy-5 (Amersham Pharmacia Biotech) were used at 1:200
dilution and incubated for 30 m. Antibody incubations were followed
by three washes of PBS containing 0.2% Tween. DNA was stained us-
ing TOTO-3 dye (Molecular Probes) in the mounting media. Cells
were viewed on a Nikon Eclipse microscope equipped with an MRC
1024 confocal laser scanning microscope system using a 60
 
3
 
 1.4 NA oil
immersion lens. 
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Immunoblotting and Immunoprecipitation
 
Cells (5 
 
3 
 
10
 
6
 
) were lysed in NP-40 lysis buffer (100 mM Tris, pH 8, 300
mM NaCl, 2 mM EDTA, 2 mM EGTA, pH 8, 2% NP-40, 2 nM PMSF, 20
mM NaF, 2 mM Na
 
3
 
VO
 
4
 
, 2 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml aprotinin) for 20 min
on ice. Microcystin (2 
 
m
 
M) was included when analyzing samples for
MEK activity. For immunoblotting to detect MAP kinase, 50–80 
 
m
 
g of
protein from the lysate was diluted in 5
 
3
 
 reducing sample buffer. Samples
were resolved by SDS-PAGE and transferred to PVDF membrane (Im-
mobilon). The membrane was blocked for 60 min in 5% milk PBS and in-
cubated with 1 
 
m
 
g/ml of anti–myc tag epitope mAb (9E10) or 0.5 
 
m
 
g/ml of
the anti–HA tag epitope mAb (12CA5). Anti–phospho-p42/p44 MAP ki-
nase antibody (Cell Signaling Technology) and anti-extracellular signal–
regulated kinase (ERK)1 and ERK2 antibodies (Promega) were used at
1:1,000. Secondary antibodies, HRP-conjugated goat anti–mouse IgG or
goat anti–rabbit polyclonal antibody (Zymed Laboratories), were de-
tected using ECL (Amersham Pharmacia Biotech). For immunoblotting
to detect cyclin B1 levels in microinjected cells, G0 CHO cells were
seeded on CELLocate coverslips (Eppendorf) and microinjected with
plasmids encoding cyclin B1, NAGT–GFP, and CDK1
 
AF
 
 and incubated
for 6 h. NAGT–GFP positive cells were counted, and cells were lysed by
spotting 5 
 
m
 
l of reducing sample buffer onto the center of the coverslip.
After collecting the lysate, a further 5 
 
m
 
l of sample buffer was spotted
onto the center of the coverslip, and the two samples were combined for
analysis by one-dimensional SDS-PAGE. To collect known numbers of
mitotic cells, cells were collected by mitotic shake-off without nocodazole
treatment and diluted to a known concentration using a cell-counting
chamber. Anti–cyclin B1 monoclonal V152 (a gift from J. Gannon and T.
Hunt) that cross-reacts with human and rodent cyclin B1 was used at a fi-
nal concentration of 2 
 
m
 
g/ml. For immunoprecipitation, cells were lysed in
NP-40 lysis buffer, and the lysate was precleared with protein A/protein G
(50:50) Sepharose beads. The supernatant was incubated for 2 h with an
anti-myc rabbit polyclonal antibody (Upstate Biotechnology) (5 
 
m
 
g/ml of
lysate) followed by a 45-min incubation with protein A/protein G (50:50)
Sepharose beads. Beads were washed three times in NP-40 lysis buffer
and used either for kinase assays or resolved by SDS-PAGE and immuno-
blotted.
 
Histone H1 Kinase Assays
 
Immunoprecipitated cyclin–CDK complexes were washed three times in
lysis buffer and once using kinase buffer (150 mM NaCl, 30 mM MgCl
 
2
 
, 60
 
m
 
M ATP, 3 mM DTT, 3 mM Na
 
3
 
VO
 
4
 
, 15 mM NaF). For each kinase reac-
tion, 15 
 
m
 
l of washed beads was mixed with 15 
 
m
 
l of kinase buffer, 2.5 
 
m
 
Ci
of [
 
g
 
-
 
33
 
P]ATP, and 1.5 
 
m
 
g of histone H1 and incubated for 30 min at 30
 
8
 
C.
The reaction was stopped by adding 5 
 
m
 
l of 4
 
3 
 
SDS sample buffer. His-
tone kinase activity was assayed after one-dimensional SDS-PAGE using
a PhosphorImager (Molecular Dynamics). 
 
Results
 
G0/G1 Phase Cells Can Be Used to Analyze the Effects 
of Specific Mitotic CDKs
 
To elucidate any differences in the biological properties
of mammalian B-type cyclins, we sought to analyze their
effects in cells lacking any other mitotic cyclins. There-
fore, we chose to express B-type cyclins in cells just after
release from serum starvation (G0/G1) when they lack
endogenous mitotic cyclins (Brandeis and Hunt, 1996).
We used CHO cells because they have a well-defined
Golgi apparatus, and we confirmed that serum-starved
CHO cells do not have endogenous mitotic cyclins by
both immunoblotting and immunofluorescence for cy-
clins A and B1 (Fig. 1, A and C). To generate active cy-
clin B–CDK1 complexes, we coexpressed cyclin B1 or B2
with a mutant form of CDK1, CDK1
 
T14A,Y15F
 
 (hereafter
referred to as CDK1
 
AF
 
) that cannot be inactivated by
either the Wee1 or Myt1 kinases (Morgan, 1995). We co-
expressed the proteins by one of two methods. In some
experiments, we transfected the cDNAs under tetracy-
cline-inducible promoters into a CHO cell line carrying a
tetracycline repressor. Immunoblotting extracts of the
cells showed that both cyclin B1 and B2 were expressed
to similar levels (Fig. 1 A) with similar kinetics and that
their expression paralleled an increase in histone H1 ki-
nase activity (data not shown). In other experiments, we
analyzed cells by time-lapse microscopy and immunoflu-
orescence after microinjecting expression constructs,
encoding the proteins under the control of the CMV
promoter. We could detect the proteins by confocal im-
munofluorescence microscopy 3 h after microinjection.
By immunoblotting these cells and quantifying the sig-
nals with NIH Image, we found that microinjected cells
reproducibly expressed approximately the same amount
of cyclin B1 as an equivalent number of mitotic cells (Fig.
1 B). (Note that this analysis underestimated the amount
of cyclin B1 in the mitotic samples because they were col-
lected by mitotic shake-off without nocodazole treat-
ment, and therefore contained some anaphase and telo-
phase cells without any B-type cyclins.) 
Theoretically, expressing active cyclin B–CDK1 com-
plexes in G1 phase cells might have caused the levels of
endogenous mitotic cyclins to increase if the kinases inac-
tivated cyclin proteolysis by phosphorylating Cdh1. How-
ever, this would be unlikely to increase mitotic cyclin lev-
els significantly because G0 cells had been shown to
downregulate mitotic cyclin transcription (Piaggio et al.,
1995; Zwicker et al., 1995). Nevertheless, we tested this
possibility by staining cells for endogenous cyclins A and
B1. This showed that none of the cells expressing ectopic
cyclin B1– or B2– CDK1
 
T14A,Y15F
 
 complexes had any en-
dogenous cyclin A or B1 (Fig. 1 C) throughout the time
course of the experiments. Therefore, we could conclude
that the effects we observed were due to the ectopic cy-
clins that we introduced.
Immunofluorescence analyses showed that the human
B-type cyclins localized correctly in CHO cells. Cyclin B1
was cytoplasmic and partially associated with microtu-
bules, whereas cyclin B2 localized to the Golgi apparatus
(Fig. 1 D). We and others had shown that cyclin B1 con-
tinuously shuttled between the cytoplasm and the nu-
cleus because of a nuclear export signal (NES) that coun-
teracted its constitutive nuclear import. Human cyclin B1
also shuttled in G0/G1 phase CHO cells because both a
myc epitope–tagged cyclin B1 (Fig. 1 E) and a cyclin B1–
GFP fusion protein (not shown) relocalized to the nu-
cleus when cells were treated with leptomycin B (LMB)
to inhibit nuclear export (Fig. 1 E, compare a and c). We
had also shown that the NH
 
2 
 
terminus of cyclin B2 had a
functional NES (Hagting et al., 1998) but found that the
full-length protein did not enter the nucleus in G2 phase
HeLa (not shown) or CHO cells treated with LMB (Fig.
1 E, compare b and d). Thus, cyclin B2 differed from cy-
clin B1 in that it remained continuously cytoplasmic, as-
sociated with the Golgi apparatus. This result agreed
with our previous observations that cyclin B2 did not
translocate to the nucleus at prophase and remained as-
sociated with membrane vesicles until it was degraded in
mitosis (Jackman et al., 1995). From these results, we
were able to conclude that human cyclins B1 and B2 had
similar subcellular targeting activities in CHO cells as
they did in human cells. 
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Figure 1.
 
(A) Human B-type cyclins are expressed to similar levels in CHO cells. Serum-starved CHO cells were transfected with plas-
mids encoding human cyclin B1 or B2 and/or CDK1
 
AF
 
 all tagged with one copy of the myc epitope and under the “tetracyclin-OFF”
promoter. Cells were incubated in the presence or absence of tetracyclin to repress or induce protein expression, respectively. 16 h after
induction, cells were lysed, and the extracts were run on one-dimensional SDS-PAGE and then immunoblotted with the 9E10 mAb to
detect the proteins. Lane 1, mock-transfected cells; lanes 2–5, transfected cells: (lane 2) cyclin B1 plasmid plus tetracyclin; (lane 3)
Cdk1
 
AF
 
; (lane 4) cyclin B1 minus tetracyclin for 16 h; (lane 5) cyclin B2 minus tetracyclin for 16 h. (B) Ectopic and endogenous cyclin 
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B1 are expressed at similar levels in CHO cells. Approximately
 
 
 
980 serum-starved CHO cells were microinjected with plasmids encod-
ing myc epitope–tagged human cyclin B1 with CDK1
 
AF
 
. 6 h after microinjection, cells were lysed and the samples were run on one-
dimensional SDS-PAGE next to lysates from 250, 500, and 1,000 mitotic cells. Proteins were immunoblotted with an anticyclin B1 mono-
clonal antibody V152 that recognizes both human and rodent cyclin B1 to detect the proteins (a gift from J. Gannon and T. Hunt). Lane
1, uninjected cells; lane 2, cells injected with cyclin B1–CDK1
 
AF
 
; lanes 3–5, 250, 500, and 1,000 mitotic HeLa cells; lane 6, 1,000 mitotic
CHO cells. M, molecular mass marker lane. Results shown are representative of three independent experiments. (C) There are no de-
tectable endogenous mitotic cyclins in serum-starved CHO cells with or without ectopic human cyclin–CDKs. (a–d) CHO cells were se-
rum starved for 24 h and then microinjected with NAGT–GFP as a Golgi apparatus and injection marker (green) and TOTO-3 to visu-
alize the DNA (blue) together with CDK1
 
AF
 
 and either cyclin B1 (a and b) or cyclin B2 (c and d). 6 h after microinjection, cells were
fixed and stained with an anti–mouse cyclin A antibody (red) (a gift from Dr. M. Carrington, University of Cambridge, Cambridge, UK)
(a and c) or with an anti–rodent cyclin B1 monoclonal antibody V143 (red) that recognizes rodent B-type cyclins but does not cross-
react with human B-type cyclins (a gift from J. Gannon and T. Hunt) (b and d). (e and f) Uninjected asynchronous (e) and serum-
starved (f) CHO cells were costained with anticyclin A (red), anticyclin B1 (green), and TOTO-3 to visualize the DNA (blue). Results
shown are representative of two independent experiments. (D and E) Human B-type cyclins localize correctly in CHO cells. Human cy-
clin B1 or B2 was tagged with one copy of the myc epitope and microinjected as cDNA under the CMV promoter into serum-starved
CHO cells. 3 h after microinjection, cells were treated or not with LMB. Cells were stained with the 9E10 mAb to detect the cyclins. (D)
Cells were costained with an antimannosidase II antibody to detect the Golgi apparatus (red in the merged images) and cyclin B1 (top
row) or cyclin B2 (bottom row) (green in the merged images). (E) Cells expressing human cyclin B1 or B2 were fixed before (a and b)
or after (c and d) treatment with 20 nM LMB for 45 min and stained for ectopically expressed cyclin B1 (a and c) or cyclin B2 (b and d). 
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Cyclin B1–CDK1 Reorganizes the Cytoskeleton and 
Chromosome Architecture but Cyclin B2–CDK1 
Does Not
 
The striking difference in the localization of the two
B-type cyclins raised the possibility that a cyclin B1–
CDK1 complex might have a different substrate specific-
ity compared with cyclin B2–CDK1. Therefore, we
analyzed changes in the subcellular architecture as a con-
sequence of expressing CDK1
 
AF
 
 with or without B-type
cyclins. CDK1
 
AF
 
 alone had no effect on any component
of the cells that we analyzed, further evidence that G0/G1
phase CHO cells did not contain any endogenous mitotic
cyclins (Fig. 2, compare l–p and q–u). When we coex-
pressed CDK1
 
AF
 
 with cyclin B1, we found that the nu-
clear lamina was rapidly solubilized (within 3 h) in almost
all the cells (Fig. 2 b; Table I). After 4 h, 
 
z
 
30% of cells
expressing cyclin B1–CDK1
 
AF
 
 had rounded up, and in
these cells the microtubules had reorganized to form a
large aster and the chromosomes had prematurely con-
densed (Fig. 2, a and c; Table I). After 6.5 h, almost all
cells expressing cyclin B1–CDK1
 
AF
 
 had rounded up.
These changes were characteristic of mitotic cells, indi-
cating that cyclin B1–CDK1
 
AF
 
 was able, directly or indi-
rectly, to induce mitotic changes in the nucleus and the
cytoplasm. Time-lapse fluorescence studies also showed
that cyclin B1–GFP translocated into the nucleus of
those cells that rounded up and condensed their DNA
(data not shown).
In contrast to the effects of cyclin B1–CDK1
 
AF
 
, overex-
pressing cyclin B2 with CDK1
 
AF
 
 did not cause any visible
changes in the chromosomes, the nuclear lamina, or the
microtubules, and all the cells remained flat and well-
attached to the dish (Fig. 2, g–i; Table I). These results
could not be explained by different levels of expression
because cyclin B1 and B2 were expressed to similar levels
in these cells (Fig. 1 A) and had similar levels of associated
H1 kinase activity (see below).
Figure 2. Different effects of cyclin B1– and B2–CDKs on subcellular architecture. Serum-starved CHO cells were unperturbed (bot-
tom row) or microinjected with expression vectors coding for a Golgi marker NAGT–GFP (d, j, and o; green in e, k, and p) and
CDK1AF, alone (third row), with cyclin B1 (top row), or with cyclin B2 (second row). After 6 h, the cells were fixed and stained with
TOTO-3 to visualize the DNA (a, g, l, and q) and with an antilamin antibody (b, h, m, and r) or an anti–b-tubulin antibody (c, i, n, and
s; red in e, k, p, and u). Antimannosidase II was used to stain the Golgi in uninjected cells (t; green in u). Note that cyclin B1 1 CDK1AF
caused the nuclear lamina to disassemble, and the solubilized lamin protein was washed out of the cell during fixation. The Golgi appa-
ratus fragmented in both cyclin B1–CDK1AF and cyclin B2–CDK1AF injected cells, but only cyclin B1 1 CDK1AF caused the microtu-
bules to become much shorter and the centrosome to nucleate more microtubules. Cells are representative of more than 120 cells ana-
lyzed in more than three separate experiments. Bars, 10 mm. 
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Both Cyclin B1– and Cyclin B2–CDK1 Cause the Golgi 
Apparatus to Disassemble
 
The targeting of cyclin B2 to the Golgi apparatus indicated
that cyclin B2–CDK1 might be restricted to phosphorylat-
ing components of the Golgi. Therefore, we assayed the
integrity of the Golgi apparatus by two different means.
First, we used an antimannosidase II or antigiantin anti-
body as a marker for the Golgi apparatus in immunofluo-
rescence analysis. Second, we used GFP fused to the Golgi
retention signal of NAGT–GFP (a gift from G. Warren,
Yale University, New Haven, CT) (Shima et al., 1997) to
analyze changes in the Golgi apparatus by time-lapse fluo-
rescence microscopy.
Expressing CDK1
 
AF
 
 alone had no effect on the integrity
of the Golgi apparatus in G0/G1 phase CHO cells as
judged by either antimannosidase II or NAGT–GFP stain-
ing (Fig. 2, o). When we coexpressed cyclin B1 with
CDK1
 
AF
 
, the Golgi broke down and took on an appear-
ance similar to that seen in early metaphase (Fig. 2, d and
e; Table I). In marked contrast to its lack of effect on the
nucleus and the microtubules, coexpressing cyclin B2 with
CDK1
 
AF
 
 also caused the Golgi to disperse (Fig. 2, j and k;
Table I). Using three different Golgi markers, we noticed
that cyclin B2–CDK1
 
AF 
 
tended to cause the Golgi to dis-
perse into fewer and larger vesicles than cyclin B1–
CDK1
 
AF
 
 (NAGT–GFP and antigiantin shown in Fig. 3;
antimannosidase, not shown). This could not be ascribed
to changes in microtubule organization instigated by cyclin
B1–CDK1
 
AF
 
 because it was also seen in cells expressing
cyclin B1–CDK1
 
AF
 
 in which the microtubule array was un-
changed (Fig 3, c, e, and g).
 
The NH
 
2 
 
Terminus of the B-type Cyclins Determines 
the Subcellular Localization and Substrates of the CDK
 
Our results indicated that cyclin B2 restricted the sub-
strate specificity of CDK1 to Golgi-associated proteins
by targeting it to the Golgi apparatus. However, an alter-
native explanation could be that the hydrophobic patch
region of cyclin B2 was only able to bind a restricted set
of substrates, although this appeared unlikely because
there were only a few changes between cyclin B1 and B2
in this region. Nevertheless, we constructed a series of
chimeras between cyclin B1 and B2 to identify the region
that targeted cyclin B2 to the Golgi apparatus. We gener-
ated chimeras in which the exchange between the cyclins
was made at conserved motifs in the two cyclins. This
showed that amino acids 1–127 were required to target
 
cyclin B2 to the Golgi apparatus (Fig. 4 A). Replacing the
NH
 
2 
 
terminus of cyclin B1 with this region of cyclin B2
(Fig. 4 A) targeted cyclin B1 to the Golgi apparatus (Fig.
4 B). Importantly, this chimera contained the whole of
the cyclin box and second cyclin fold of cyclin B1, includ-
ing the hydrophobic patch of cyclin B1 and was able to
bind and activate CDK1 to a similar extent as wild-type
cyclin B1 (Fig. 4 D). When we coexpressed the B2–B1
chimera with CDK1
 
AF
 
, it was now only able to cause
the Golgi apparatus to disassemble (Fig. 4 C). It did
not cause chromosome condensation or nuclear lamina
breakdown (Fig. 4 C), nor did it alter the microtubule ar-
ray or translocate to the nucleus in any of the cells that
we assayed.
From these results, we predicted that the converse chi-
mera, one where the cyclin box and second cyclin fold of
cyclin B2 was targeted to the cytoplasm by the NH
 
2 
 
termi-
nus of cyclin B1, would confer on cyclin B2 the broader
substrate specificity of cyclin B1. This prediction was con-
firmed when we coexpressed a B1–B2 chimera (Fig. 5 A)
with CDK1
 
AF
 
 and found that it was localized throughout
the cytoplasm and not restricted to the Golgi apparatus
(Fig. 5 B). This chimera also bound and activated CDK1 to
a similar extent as the wild-type protein (Fig. 4 D). Al-
though the chimera had the hydrophobic patch and cyclin
folds of cyclin B2, it was able to cause the microtubules to
reorganize in addition to causing Golgi disassembly (Fig. 5
C). However, the chimera was not able to shuttle into the
nucleus in the presence of LMB (data not shown). In
agreement with its restricted cytoplasmic localization, it
had no effect on either the condensation state of the DNA
or the integrity of the nuclear lamina (Fig. 5 C).
 
B-type Cyclin–CDK1 Kinases Do Not Require MEK to 
Disassemble the Golgi Apparatus
 
Time-lapse fluorescence microscopy using NAGT–GFP
showed that both cyclin B1– and cyclin B2–CDK1 com-
plexes caused the Golgi to begin to disassemble at approx-
imately the same time after microinjection (data not
shown). This raised the question of whether B-type cyclin–
CDK complexes required MEK to cause Golgi disassem-
bly. In our microinjection regime, we used serum-starved
cells to which we added 2% serum to aid recovery from the
microinjection before analyzing them 3 h later. Although
this treatment did not generate any endogenous mitotic cy-
clins over the time course of our experiments (Fig. 1 C), it
did activate MEK (Fig. 6, A and B). However, none of the
 
Table I. Effect of Different B-type Cyclin–CDKs on Subcellular Architecture
 
3–4 h 6–6.5 h
Injection
Minimum 
number of 
experiments
Disassembled 
Golgi
Aster-like 
microtubules
Solubilized 
lamina
Condensed 
chromosome
Minimum 
number of 
experiments
Disassembled 
Golgi
Aster-like 
microtubules
Solubilized 
lamina
Condensed 
chromosomes
 
% (n) % (n)
 
Cyclin B1 
 
1 
 
CDK1
 
AF
 
4 92 (89) 28 (95) 81 (59) 36 (59) 3 95 (103) 63 (70) 89 (82) 89 (82)
Cyclin B2 
 
1 
 
CDK1
 
AF
 
4 88 (73) 0 (26) 0.6 (47) 0 (27) 3 90 (120) 1 (53) 1 (31) 1 (31)
CDK1
 
AF
 
3 15 (79) 3 (30) 2 (49) 2 (49) 2 12 (74) 6 (30) 0 (44) 0 (44)
B1–B2 chimera 
 
1 
 
CDK1
 
AF
 
3 90 (54) 39 (51) 2 (48) 2 (48) 2 93 (48) 67 (44) 0 (31) 0 (31)
B2–B1 chimera 
 
1 
 
CDK1
 
AF
 
3 88 (94) 8 (49) 2 (45) 2 (48) 2 96 (49) 0 (22) 0 (28) 0 (28)
The percentage of cells with disassembled Golgi apparatus, microtubules reorganized to form asters, solubilized nuclear lamins, and condensed chromosomes at 3–3.5 and 6–6.5 h
after injection with specific cyclins and CDK constucts are given along with the number of cells scored as positive for the injection marker. 
The Journal of Cell Biology, Volume 152, 2001 952 
Draviam et al.
 
 Localization Determines CDK Specificity
 
953
 
cells disassembled their Golgi apparatus in the absence of
mitotic cyclin–CDKs (Fig. 2, o and t).
To analyze the effect of the mitotic cyclin–CDKs in the
absence of active MEK, we treated serum-starved cells with
the MEK kinase inhibitors PD98059 (20 
 
m
 
M) and U0126 (25
 
m
 
M) for 1 h before microinjection and continued to incubate
cells with these inhibitors after microinjection. We assayed
MEK activity by immunoblotting cell lysates with an anti–
phospho-MAP kinase antibody that only recognized MAP
kinases that had been phosphorylated by MEK (Fig. 6 A).
 
Figure 3.
 
Cyclin B1–CDK1
 
AF
 
 and cyclin B2–CDK1
 
AF
 
 have different effects on the Golgi apparatus. Serum- starved CHO cells were mi-
croinjected with expression vectors coding for a Golgi marker NAGT–GFP (c and d) and cyclin B1 with CDK1AF (a, c, e, and g) or cy-
clin B2 with CDK1AF (b, d, f, and h). Cells were fixed and stained with antimannosidase II (not shown) and antigiantin (a and b, arrows
denote uninjected cells) or with an anti–b-tubulin antibody (e and f). The merge shown (g and h) is between antitubulin and NAGT–
GFP. Note that cyclin B1–CDK1AF causes the Golgi to break down into smaller and more numerous vesicles than does cyclin B2–
CDK1AF in cells before observable changes in the cytoskeleton. Cells are representative of .250 cells analyzed in .10 separate experi-
ments. Bars, 10 mm.
Figure 4. The NH2 terminus of cyclin B2 targets cyclin B1 to
the Golgi and restricts its activity. (A) Schematic diagram of
the chimera constructed between cyclin B2 and cyclin B1. Cy-
clin B2 is represented by a solid line and cyclin B1 by an open
rectangle. The cyclin B2–B1 mutant exchanges at the sequence
LCS (S130 in cyclin B2, and S177 in cyclin B1) in both cyclins.
The hydrophobic patch is represented by the filled oval. (B)
The NH2 terminus of cyclin B2 targets cyclin B1 to the Golgi
apparatus. Serum-starved CHO cells were microinjected with
expression vectors coding for a Golgi marker NAGT–GFP
(green) and with a myc epitope–tagged cyclin B2–B1 chimera.
After 6 h, the cells were fixed and stained with an anti-myc
epitope antibody (red). One uninjected cell and one cell ex-
pressing the chimera are shown. (C) The NH2 terminus of cy-
clin B2 confers the properties of cyclin B2 on cyclin B1. Se-
rum-starved CHO cells were microinjected with expression
vectors coding for a Golgi marker NAGT–GFP and CDK1AF
with a cyclin B2–B1 chimera. After 6 h, the cells were fixed
and stained with an anti–b-tubulin antibody or with an anti-
lamin antibody and TOTO-3 to visualize the DNA. Cells are
representative of .100 cells analyzed in three separate experi-
ments. (D) Cyclin B chimeras bind and activate CDK1 to a
similar extent as wild-type cyclins. Human 293T cells were
mock transfected with an empty vector or transfected with un-
tagged CDK1AF and myc epitope–tagged cyclins B1, B2, or the
B1–B2 or B2–B1 chimera. 12 h after transfection, cells were
lysed with NP-40 lysis buffer and the transfected cyclins were
immunoprecipitated with an anti-myc epitope antibody. Im-
munoprecipitates were processed for H1 kinase assays and the
amount of phosphate incorporated was quantitated and nor-
malized to the H1 kinase activity in the cyclin B1–CDK sam-
ple. In parallel, immunoprecipitates were immunoblotted with an anti-CDK1 monoclonal (inset) and an anti-myc epitope anti-
body (not shown) to demonstrate that equivalent amounts of cyclins were immunoprecipitated. Results shown are representative
of two independent experiments. Bars, 10 mm.The Journal of Cell Biology, Volume 152, 2001 954
As a loading control, we immunoblotted the same extracts
with anti-ERK1 and anti-ERK2 antibodies that recognized
both the phosphorylated and the unphosphorylated forms
of ERK1 and ERK2 (Fig. 6 B). Incubating cells with U0126
and PD98059 prevented any phosphorylation of MAP ki-
nase when 2% serum was added back to serum-starved cells,
showing that MEK activity was inhibited (Fig. 6 A). Never-
theless, microinjecting cyclin B1–CDK1AF or cyclin B2–
CDK1AF into U0126- and PD98059-treated cells caused the
Golgi apparatus to disassemble with similar efficiency com-
pared with cells incubated without MEK inhibitors (Fig. 6
C). Thus, MEK activity was not required for mitotic cyclin–
CDKs to break down the Golgi apparatus in living cells.
Furthermore, the Golgi disassembled by a similar mecha-
nism to that seen in mitosis because it was recognized by a
polyclonal antibody directed against the Ser25-phosphory-
lated form of the Golgi matrix protein GM130 (Lowe et al.,
2000). GM130 had been shown to be phosphorylated on
Ser25 only in mitosis, and this phosphorylation was required
for Golgi disassembly (Lowe et al., 1998, 2000). Both cyclin
B1–CDK1AF and cyclin B2–CDK1AF generated the phos-
pho-Ser25 form of GM130 in the presence or absence of
MEK activity, and this was coincident with Golgi disassem-
bly (Fig. 6 C). Activating MEK by adding back serum in the
absence of any mitotic cyclin–CDKs did not generate Ser25-
phosphorylated GM130 (data not shown).
We also excluded the possibility that MEK was required
to break down the Golgi apparatus during normal mitosis,
that is, in cells with endogenous levels of B-type cyclin–
CDK activity. We treated G2 phase CHO cells with the
same concentrations of U0126 and PD98059 that we used
for serum-stimulated cells and found that this inhibited
MEK in G2 phase cells (Fig. 7, A and B). These cells pro-
ceeded through mitosis at the same rate as untreated cells
(Draviam, V.M., and J. Pines, manuscript in preparation),
and there was no difference between control cells and
MEK-inhibited cells in disassembly of the Golgi apparatus
as analyzed by confocal immunofluorescence microscopy
(Fig. 7 C). These data showed that neither MEK, ERK1,
nor ERK2 was required for the disassembly of the Golgi
apparatus in normal mitosis.
Discussion
Subcellular Localization Has a Profound Influence on 
the Substrates of Mitotic Cyclin–CDKs
In this paper, we show that subcellular localization pro-
foundly affects the substrate specificity of B-type cyclin–
CDK complexes. We have shown that CDK1 activated by
human cyclin B1 is able to reorganize nuclear, cytoskele-
tal, and membrane compartments in the cell, whereas
when activated by cyclin B2 it is only able to disassemble
the Golgi apparatus. Furthermore, directing cyclin B1 to
the Golgi apparatus restricts its ability to effect all but the
reorganization of the Golgi apparatus. Equally, if cyclin
B2–CDK1AF is liberated from the Golgi apparatus, it is
able to reorganize the cytoskeleton in a similar manner to
wild-type cyclin B1–CDK1AF. Thus, the primary control
on substrate selection by the mitotic cyclins is their subcel-
lular localization, and this is distinct from any substrate-
binding role of the hydrophobic patch of the cyclin box.
Figure 5. The NH2 terminus of cyclin B1 targets cyclin B2 to the
cytoplasm and broadens its activity. (A) Schematic diagram of the
chimera constructed between cyclin B1 and cyclin B2. Cyclin B1 is
represented by an open rectangle and cyclin B2 by a solid line. The
cyclin B1–B2 mutant exchanges at the sequence LCQ in both cy-
clins (Q106 in B1, and Q144 in B2). (B) The NH2 terminus of cyclin
B1 targets cyclin B2 to the cytoplasm. Serum-starved CHO cells
were microinjected with expression vectors coding for a Golgi
marker NAGT–GFP (green) and with a myc epitope–tagged cy-
clin B1–B2 chimera. After 6 h, the cells were fixed and stained with
an anti-myc epitope antibody (red). (C) The NH2 terminus of cy-
clin B1 confers some of the properties of cyclin B1 on cyclin B2.
Serum-starved CHO cells were microinjected with expression vec-
tors coding for a Golgi marker NAGT–GFP and CDK1AF with a
cyclin B1–B2 chimera. After 6 h, the cells were fixed and stained
with an anti–b-tubulin antibody or with an antilamin antibody and
TOTO-3. Cells are representative of .150 cells analyzed in three
separate experiments. Bars, 10 mm.Draviam et al. Localization Determines CDK Specificity 955
Figure 6. Cyclin B–CDK1 complexes will disassemble the Golgi apparatus in a physiologically relevant manner in the absence of
MEK activity. (A and B) CHO cells were incubated in DME containing 0.1% serum for 3 d (lanes 3 and 7), after which DME with
2% FCS was added back in the presence (lanes 1 and 5) or absence (lanes 4 and 8) of the MEK inhibitors, U0126 (25 mM) and
PD98059 (20 mM). MEK inhibitors were also added to cells in the absence of serum (lanes 2 and 6). Cells were lysed after 10 min
(lanes 1–4) or 3 h (lanes 5–8), and whole cell extracts were probed with an anti–phospho-MAP kinase antibody ( A) and subse-
quently reprobed with an antibody that recognizes all forms of MAP kinase (B) as a loading control. Results shown are represen-
tative of three independent experiments. (C) CHO cells were incubated in DME containing 0.1% serum for 3 d and then microin-
jected with expression constructs for NAGT–GFP (left; and green, in right panels) with either cyclin B1 and CDK1AF (top
panels), cyclin B2 and CDK1AF (middle panels), or CDK1AF (bottom panels) in the presence of 2% serum and MEK inhibitors as
in A and B. After 3 h, cells were fixed and stained with an antibody that recognizes the phosphorylated form of GM130 (center;
and red, in right panels) and an anti–b-tubulin antibody (blue in right panels). Results shown are representative of two indepen-
dent experiments. Bars, 10 mm.The Journal of Cell Biology, Volume 152, 2001 956
Figure 7. MEK activity is not required for Golgi
disassembly in normal mitosis. (A and B) CHO
cells were serum starved for 36 h and then stimu-
lated with DME plus 10% serum. At 18 h, the
MEK inhibitors U0126 (25 mM) and PD98059
(20 mM) were added to one set of cells. Samples
were taken for flow cytometry analysis and for
immunoblotting at 45 min and 2, 3, and 6 h af-
ter adding MEK inhibitors while cells were
progressing through mitosis. Flow cytometry
showed that the peak of mitosis was at 3 h after
addition of inhibitors (data not shown). Samples
were processed to detect phophorylated ERK1
and ERK2 (A) and total ERK1 and ERK2 (B)
as in the legend to Fig. 6. Results shown are rep-
resentative of three independent experiments.
(C) CHO cells were serum starved and refed
and the MEK inhibitors U0126 (25 mM) and
PD98059 (20 mM) were added to one set of G2
phase cells as in A and B. DMSO was added to
the other set. 3 h later, cells were processed for
immunofluorescence with antigiantin antibodies
(green) and TOTO-3 to stain the DNA (blue).
Cells at various stages of mitosis are shown and
are representative of .100 cells examined in
three independent experiments.
Shortly after expressing cyclin B1–CDK1AF, only a mi-
nority of G0/G1 cells have reorganized microtubules and
condensed their DNA, but almost all have disassembled
the Golgi apparatus and solubilized the nuclear lamina.
This may indicate that cyclin B1–CDK1 has a greater af-
finity for the nuclear lamins and for Golgi apparatus sub-
strates than for chromosomal or microtubule-associated
proteins. Alternatively, there may be additional factors re-
quired for chromosome condensation and microtubule
disassembly that are limiting in G0/G1 phase cells.
Surprisingly, we find that the nuclear membrane re-
mains intact (as judged by differential interference con-
trast microscopy) in cells where the nuclear lamins have
been solubilized by cyclin B1–CDK1. Therefore, cyclin
B1–CDK1 does not appear to be the protein kinase re-
sponsible for nuclear envelope, as opposed to nuclear lam-
ina breakdown in agreement with studies on nuclear mem-
brane assembly and disassembly in vitro (Pfaller et al.,
1991). The ability of cyclin B1–CDK1AF to phosphorylate
both nuclear and cytoplasmic substrates is likely to be be-Draviam et al. Localization Determines CDK Specificity 957
cause it can shuttle between the nucleus and the cytoplasm
during interphase. In contrast, neither cyclin B2 nor the
cyclin B1–B2 chimera are able to alter the nuclear archi-
tecture, and this correlates with their inability to enter the
nucleus in the presence of LMB.
Thus, there is a dramatic difference in the biological ac-
tion of cyclins B1 and B2 even though both are targeted to
the cytoplasm. Miller and Cross (2000) showed that redi-
recting a nuclear cyclin, a truncation mutant of the bud-
ding yeast Cln3p, to the cytoplasm with an exogenous nu-
clear export sequence perturbed its ability to complement
a strain deficient in CLN3. They also showed that this mu-
tant protein appeared to take on some of the properties of
the cytoplasmic Cln2 (Miller and Cross, 2000). We have
shown here that it is also important where in the cyto-
plasm the cyclin is directed. Subcellular localization could
also have an important role in the specialization of differ-
ent nuclear cyclin–CDKs that may have been overlooked,
especially given that the nucleus is composed of distinct
regions and structures to which proteins are specifically
targeted (for review see Lamond and Earnshaw, 1998).
Thus, one can envisage several specific subcellular sites
where protein kinases, phosphatases, and other regulators
integrate intracellular signals in functional isolation from
the rest of the cell. These sites of signal integration would
eventually have to be coupled to each other to coordinate
entry into mitosis. This could most obviously be achieved
by relocalizing an activated enzyme from one subcellular
compartment to another, for example, by the translocation
of cyclin B1–CDK1 to the nucleus at the end of prophase.
Similarly, it is important to take into account the local-
ization of ectopically expressed proteins when interpreting
studies that appear to show complementation between cy-
clins. For example, Clb2 is able to perform the functions of
Clb5 when it is overexpressed from the strong GAL pro-
moter but not when it is driven by the much weaker Clb5
promoter (Cross et al., 1999). This effect was interpreted
as evidence in favor of the specificity of substrate selection
by the hydrophobic patch of Clb5, but it might also be ex-
plained by excess Clb2 being able to localize to late origins
of DNA replication that are normally targeted by Clb5. In
fission yeast, the observation that low levels of cdc13/cdc2
drive S phase and high levels drive M phase (Stern and
Nurse, 1996) could be explained should higher levels of
cdc13/cdc2 bind to low affinity sites where they encounter
M phase substrates.
B-type Cyclin–CDKs Can Disassemble the Golgi 
Apparatus without MEK
We find that cyclin B1–CDK1 and cyclin B2–CDK1 are
equally able to initiate Golgi disassembly, although nei-
ther kinase alone is able to reproduce the complete disas-
sembly observed in mitotic cells. However, the breakdown
of the Golgi apparatus induced by cyclin B1–CDK1 in G0/
G1 phase is accompanied by the phosphorylation of
GM130 on Ser25 that is characteristic of Golgi disassem-
bly in mitosis. When GM130 is phosphorylated on Ser25,
vesicles continue to be shed from the Golgi but cannot
bind again because the vesicle protein p115 cannot bind
phospho-GM130 (Lowe et al., 1998, 2000). Ser25 of
GM130 can be directly phosphorylated in vitro by cyclin
B1– and cyclin B2–CDK1 complexes (Lowe et al., 1998).
The nature of the other proteins required to effect com-
plete Golgi disassembly is unclear but they do not appear
to include MEK because we have shown here that actively
dividing cells disassemble their Golgi apparatus in the
prescence of the MEK inhibitors, U0126 and PD98059.
Warren and colleagues (Misteli and Warren, 1995a;
Lowe et al., 1998, 2000) have concluded that B-type cy-
clin–CDKs, rather than the Golgi-associated MEK1 postu-
lated by Malhotra and colleagues  (Acharya et al., 1998;
Colanzi et al., 2000; Kano et al., 2000), are responsible for
Golgi fragmentation at mitosis. Our results support this
conclusion. GM130 was phosphorylated on Ser25 in cells
expressing either cyclin B1– or B2–CDK1AF , and there
was no difference in the ability of either B-type cyclin–
CDK1 to cause Golgi disassembly, or to phosphorylate
GM130, in the presence or absence of the MEK inhibitors
U0126 and PD98059. These inhibitors also have no effect
on the breakdown of the Golgi apparatus in cells undergo-
ing normal mitosis. Nor do our results support the model
that MEK activity is required for the initial stages of Golgi
disassembly and cyclin–CDK activity for subsequent steps
(Kano et al., 2000). One difference between our analysis
and the studies that have implicated a role for MEK in mi-
totic Golgi disassembly is that we have analyzed disassem-
bly in intact, living cells rather than in vitro systems using
permeabilized cells or purified membranes added to cyto-
sol. Because we have not salt-treated or permeabilized our
cells, we have avoided the possibility that protein kinases
may be able to phosphorylate substrates with which they
do not normally interact.
Our results demonstrate that localization profoundly in-
fluences substrate selection by mitotic cyclin–CDKs. This
may also be extrapolated to other protein kinase families
that show specific subcellular localizations. In addition,
protein kinases that exhibit dynamic changes in their sub-
cellular localization could perform different functions at
different times depending on where they are in the cell
(for review see Pines, 1999). Clearly, a complete under-
standing of the function of a protein kinase must take ac-
count of both when it is active and where it is localized.
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